David A Talan1,2, Frank Lovecchio3, Fredrick M Abrahamian4, David J Karras5, Mark T Steele6, Richard E Rothman7, Anusha Krishnadasan4, William R Mower8, Rebecca Hoagland9, Gregory J Moran1,2. 1. Department of Emergency Medicine. 2. Division of Infectious Diseases, Department of Medicine, Olive View-UCLA Medical Center, David Geffen School of Medicine at UCLA. 3. Department of Emergency Medicine, Maricopa Medical Center, University of Arizona and Mayo Graduate School of Medicine, Phoenix. 4. Departmentof Emergency Medicine. 5. Department of Emergency Medicine, Temple University Medical Center, Temple University School of Medicine, Philadelphia, Pennsylvania. 6. Department of Emergency Medicine, Truman Medical Center, University of Missouri-Kansas City School of Medicine. 7. Department of Emergency Medicine, Johns Hopkins Medical Center, Johns Hopkins School of Medicine, Baltimore, Maryland. 8. Department of Emergency Medicine, Ronald Reagan Medical Center, David Geffen School of Medicine at UCLA. 9. Cota Enterprises, Inc, McLouth, Kansas.
Abstract
BACKGROUND: With the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) in the United States, visits for skin infections greatly increased. Staphylococci and streptococci are considered predominant causes of wound infections. Clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly prescribed, but the efficacy of TMP-SMX has been questioned. METHODS: We conducted a randomized, double-blind, superiority trial at 5 US emergency departments. Patients >12 years of age with an uncomplicated wound infection received oral clindamycin 300 mg 4 times daily or TMP-SMX 320 mg/1600 mg twice daily, each for 7 days. We compared the primary outcome, wound infection cure at 7-14 days, and secondary outcomes through 6-8 weeks after treatment, in the per-protocol population. RESULTS:Subjects had a median age of 40 years (range, 14-76 years); 40.1% of wound specimens grew MRSA, 25.7% methicillin-susceptible S. aureus, and 5.0% streptococci. The wound infection was cured at 7-14 days in 187 of 203 (92.1%) clindamycin-treated and 182 of 198 (91.9%) TMP-SMX-treated subjects (difference, 0.2%; 95% confidence interval [CI], -5.8% to 6.2%; P = not significant). The clindamycin group had a significantly lower rate of recurrence at 7-14 days (1.5% vs 6.6%; difference, -5.1%; 95% CI, -9.4% to -.8%) and through 6-8 weeks following treatment (2.0% vs 7.1%; difference, -5.1%; 95% CI, -9.7% to -.6%). Other secondary outcomes were statistically similar between groups but tended to favor clindamycin. Adverse event rates were similar. CONCLUSIONS: In settings where MRSA is prevalent, clindamycin and TMP-SMX produce similar cure and adverse event rates among patients with an uncomplicated wound infection. Further study evaluating differential effects of antibiotics on recurrent infection may be warranted. CLINICAL TRIALS REGISTRATION: NCT00729937.
RCT Entities:
BACKGROUND: With the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) in the United States, visits for skin infections greatly increased. Staphylococci and streptococci are considered predominant causes of wound infections. Clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly prescribed, but the efficacy of TMP-SMX has been questioned. METHODS: We conducted a randomized, double-blind, superiority trial at 5 US emergency departments. Patients >12 years of age with an uncomplicated wound infection received oral clindamycin 300 mg 4 times daily or TMP-SMX 320 mg/1600 mg twice daily, each for 7 days. We compared the primary outcome, wound infection cure at 7-14 days, and secondary outcomes through 6-8 weeks after treatment, in the per-protocol population. RESULTS: Subjects had a median age of 40 years (range, 14-76 years); 40.1% of wound specimens grew MRSA, 25.7% methicillin-susceptible S. aureus, and 5.0% streptococci. The wound infection was cured at 7-14 days in 187 of 203 (92.1%) clindamycin-treated and 182 of 198 (91.9%) TMP-SMX-treated subjects (difference, 0.2%; 95% confidence interval [CI], -5.8% to 6.2%; P = not significant). The clindamycin group had a significantly lower rate of recurrence at 7-14 days (1.5% vs 6.6%; difference, -5.1%; 95% CI, -9.4% to -.8%) and through 6-8 weeks following treatment (2.0% vs 7.1%; difference, -5.1%; 95% CI, -9.7% to -.6%). Other secondary outcomes were statistically similar between groups but tended to favor clindamycin. Adverse event rates were similar. CONCLUSIONS: In settings where MRSA is prevalent, clindamycin and TMP-SMX produce similar cure and adverse event rates among patients with an uncomplicated wound infection. Further study evaluating differential effects of antibiotics on recurrent infection may be warranted. CLINICAL TRIALS REGISTRATION: NCT00729937.
Authors: Gregory J Moran; Anusha Krishnadasan; Rachel J Gorwitz; Gregory E Fosheim; Linda K McDougal; Roberta B Carey; David A Talan Journal: N Engl J Med Date: 2006-08-17 Impact factor: 91.245
Authors: Asha C Bowen; Rachael A Lilliebridge; Steven Y C Tong; Robert W Baird; Peter Ward; Malcolm I McDonald; Bart J Currie; Jonathan R Carapetis Journal: J Clin Microbiol Date: 2012-10-10 Impact factor: 5.948
Authors: David A Talan; William R Mower; Anusha Krishnadasan; Fredrick M Abrahamian; Frank Lovecchio; David J Karras; Mark T Steele; Richard E Rothman; Rebecca Hoagland; Gregory J Moran Journal: N Engl J Med Date: 2016-03-03 Impact factor: 91.245
Authors: Derek J Williams; William O Cooper; Lisa A Kaltenbach; Judith A Dudley; David L Kirschke; Timothy F Jones; Patrick G Arbogast; Marie R Griffin; C Buddy Creech Journal: Pediatrics Date: 2011-08-15 Impact factor: 7.124
Authors: Binh An Diep; Henry F Chambers; Christopher J Graber; John D Szumowski; Loren G Miller; Linda L Han; Jason H Chen; Felice Lin; Jessica Lin; Tiffany HaiVan Phan; Heather A Carleton; Linda K McDougal; Fred C Tenover; Daniel E Cohen; Kenneth H Mayer; George F Sensabaugh; Françoise Perdreau-Remington Journal: Ann Intern Med Date: 2008-01-30 Impact factor: 25.391
Authors: Daniel J Pallin; Daniel J Egan; Andrea J Pelletier; Janice A Espinola; David C Hooper; Carlos A Camargo Journal: Ann Emerg Med Date: 2008-01-28 Impact factor: 5.721
Authors: Patrick G Hogan; Marcela Rodriguez; Allison M Spenner; Jennifer M Brenneisen; Mary G Boyle; Melanie L Sullivan; Stephanie A Fritz Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079
Authors: Margaret Carrel; Michihiko Goto; Marin L Schweizer; Michael Z David; Daniel Livorsi; Eli N Perencevich Journal: Antimicrob Resist Infect Control Date: 2017-06-05 Impact factor: 4.887
Authors: Rahul S Kamath; Deepthi Sudhakar; Julianna G Gardner; Vagish Hemmige; Hossam Safar; Daniel M Musher Journal: Open Forum Infect Dis Date: 2018-01-12 Impact factor: 3.835
Authors: Dennis Nurjadi; Quan Chanthalangsy; Elfi Zizmann; Vanessa Stuermer; Maximilian Moll; Sabrina Klein; Sébastien Boutin; Klaus Heeg; Philipp Zanger Journal: Microbiol Spectr Date: 2021-10-27
Authors: Daniele Roberto Giacobbe; Silvia Dettori; Silvia Corcione; Antonio Vena; Chiara Sepulcri; Alberto Enrico Maraolo; Francesco Giuseppe De Rosa; Matteo Bassetti Journal: Infect Drug Resist Date: 2022-04-22 Impact factor: 4.177
Authors: David A Talan; William R Mower; Frank A Lovecchio; Richard E Rothman; Mark T Steele; Katelyn Keyloun; Patrick Gillard; Ronald Copp; Gregory J Moran Journal: Acad Emerg Med Date: 2021-05-05 Impact factor: 3.451